NuCana
Yahoo Finance • 2 months ago
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.55%
Investing.com – U.S. stocks were higher after the close on Friday, as gains in the Consumer Services, Consumer Goods and Industrials sectors led shares higher. At the close in NYSE, the Dow Jones Industrial Average added 0.55% to hit a ne... Full story
Yahoo Finance • 12 months ago
NuCana Reports Third Quarter 2023 Financial Results and Provides Business Update
Announced Encouraging Updates from NUC-3373 and NUC-7738 Demonstrating Promising Efficacy and Safety Data Pipeline Continues to Advance with Data Updates Expected for all Programs in 2024 Well Capitalized with Anticipated Cash Runway int... Full story
Yahoo Finance • 12 months ago
NuCana Announces Listing Transfer to Nasdaq Capital Market
EDINBURGH, United Kingdom, Nov. 10, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announced today that it has received approval from Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”)... Full story
Yahoo Finance • 12 months ago
NuCana to Present at the Jefferies London Healthcare Conference
EDINBURGH, United Kingdom, Nov. 08, 2023 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the... Full story
Yahoo Finance • last year
NuCana to Participate in the Truist Securities 2023 BioPharma Symposium
EDINBURGH, United Kingdom, Nov. 01, 2023 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will host one-on-one meetings at the Truist Secur... Full story
Yahoo Finance • last year
NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
Data from the NuTide:701 Study Indicate NUC-7738 May Potentiate the Activity of Anti-PD-1 Agents in Patients who were Refractory to or Progressed on Prior Immunotherapy, including Anti-PD-1 Therapy Several Patients Achieved Reductions in... Full story
Yahoo Finance • last year
NuCana Presents Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
NUC-3373 Demonstrates Promising Anti-Tumor Activity and a Favorable Safety Profile as part of NUFIRI-bevacizumab and NUFOX-bevacizumab in Second-line Colorectal Cancer Patients Several Second-line Colorectal Cancer Patients in the NuTide:... Full story
Yahoo Finance • last year
NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
EDINBURGH, United Kingdom, Sept. 18, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced four presentations at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 being held Oct... Full story
Yahoo Finance • last year
NuCana Reports Second Quarter 2023 Financial Results and Provides Business Update
On Track to PresentData Updates from All Ongoing Clinical Studiesin the Second Half of 2023 Well Capitalized with Anticipated Cash Runway into 2025 EDINBURGH, United Kingdom, Aug. 16, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA)... Full story
Yahoo Finance • last year
NuCana Reports First Quarter 2023 Financial Results and Provides Business Update
Multiple Important Data Readouts Remain on Track for 2023 Well Capitalized with Anticipated Cash Runway into 2025 EDINBURGH, United Kingdom, May 17, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the f... Full story
Yahoo Finance • last year
NuCana Announces Receipt of Nasdaq Notice
EDINBURGH, United Kingdom, May 12, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that it received written notification (the “Notification Letter”) from The Nasdaq Stock Market LLC ("Nasdaq") dated May 9, 2023, indicating t... Full story
Yahoo Finance • 2 years ago
15 Top Performing European Stocks So Far in 2023
In this article, we will take a look at the 15 top performing European stocks so far in 2023. To see more such companies, go directly to 5 Top Performing European Stocks So Far in 2023. The Bank of England on March 23 raised its benchmark... Full story
Yahoo Finance • 2 years ago
Technical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana’s ‘190 Patent is Not Valid
MUNICH, Germany, March 24, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that, following a hearing on March 24, 2023, the Technical Board of Appeal (the “TBA”) of the European Patent Office (the “EPO”) issued an oral judge... Full story
Yahoo Finance • 2 years ago
NuCana to Participate in Two Upcoming Investor Conferences
EDINBURGH, United Kingdom, Feb. 28, 2023 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will participate in two upcoming investor confere... Full story
Yahoo Finance • 2 years ago
NuCana Announces Receipt of NASDAQ Notice
EDINBURGH, United Kingdom, Jan. 06, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that it received written notification (the “Notification Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated January 3, 2023, indicat... Full story
Yahoo Finance • 2 years ago
NuCana Reports Third Quarter 2022 Financial Results and Provides Business Update
Multiple Data Readouts on Track for the Remainder of 2022 and the First Half of 2023 Well Capitalized with Anticipated Cash Runway into 2025 EDINBURGH, United Kingdom, Nov. 16, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announc... Full story
Yahoo Finance • 2 years ago
NuCana Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022
NUC-3373 Potentiates Immunogenic Activity in Lung Cancer Cells Pembrolizumab Activity Increased by NUC-3373 in Lung Cancer Cells NuCana has Initiated the NuTide:303 Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel BARCEL... Full story
Yahoo Finance • 2 years ago
NuCana Announces Presentations at the European Society for Medical Oncology (ESMO) Congress 2022
EDINBURGH, United Kingdom, Sept. 06, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced two presentations at the European Society for Medical Oncology (ESMO) Congress 2022 being held September 9-13, 2022 at the Paris Expo Porte... Full story
Yahoo Finance • 2 years ago
NuCana to Participate in Citi's 17th Annual BioPharma Conference
EDINBURGH, United Kingdom, Aug. 31, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that management will host one-on-one meetings at Citi's 17th Annual BioPharma Conference. Event: Citi's 17th Annual BioPharma Confere... Full story
Yahoo Finance • 2 years ago
NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement
EDINBURGH, United Kingdom, July 27, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), (“NuCana” or the “Company”), announced that it has received a written notification (the “Notification Letter”) from the Listing Qualifications Depart... Full story
